Skip to main content
MyPeptideDosagesMyPeptideDosages
blend20MG

BPC-157 + TB-500

20MG Protocol

BPC-157 + TB-500 20MG

Injection Freq.

Once daily

Cycle Sched.

4–8 weeks; optional cycling with 6-week breaks between courses

Reconstitution

3.0 mL BAC water

Tissue repair / wound‑healing support in animal models
Tendon‑repair and anti‑inflammatory properties (preclinical)
Gastroprotective/ulcer‑healing effects attributed to BPC‑157 (preclinical)
Favorable safety observations in cited preclinical/tolerability reports
1

Reconstitution Requirements

  • 3.0 mL BAC water
StepWeek RangeDoseUnits
1Weeks 1–2500 mcg (0.5 mg)7.5
2Weeks 3–4666 mcg (0.67 mg)10
3Weeks 5–81,000 mcg (1.0 mg)15

Once daily

4–8 weeks; optional cycling with 6-week breaks between courses

Mechanistically, this higher‑content version is described similarly to the 10 mg blend: pairing BPC‑157’s cytoprotective/angiogenic signaling with TB‑500’s actin‑mediated support for cell migration and tissue remodeling. BPC‑157 is presented as interacting with nitric‑oxide and growth‑factor pathways and showing broad protective effects across multiple tissues in preclinical work, including GI and musculoskeletal systems. TB‑500 (thymosin β4) is framed as supporting wound healing by enabling cells to move into injured areas, reducing inflammation, and assisting regeneration processes. The ‘why blend’ rationale remains complementary coverage of the healing timeline—supporting vascular/biochemical signals and the cellular mechanics of repair. The page also highlights a wide preclinical safety margin for BPC‑157 and notes that TB‑500 has been tolerated at high doses in human contexts, but it still emphasizes that long‑term human safety data for research‑peptide use is limited. In practical terms, the mechanism description is meant to justify use in soft‑tissue recovery protocols that prioritize consistent dosing and careful site rotation to minimize local irritation.
Mild injection‑site redness or itching
Rare transient dizziness or nausea (reported)
Limited long‑term human safety data
  • Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
  • Add diluent slowly down the vial wall to minimize foaming
  • Gently swirl/roll until fully dissolved (do not shake)
  • Label vial with reconstitution date and concentration; protect from light
  • Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
  • Avoid repeated freeze–thaw cycles
  • Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
  • Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)

Related peptide protocols

More research-backed dosing guides in this category.